Discover NEW published data on the advantages of using a personalized, tumor-informed circulating tumor DNA (ctDNA) test to design oncology clinical trials. Learn how Signatera, awarded 3 breakthrough technology designations, can be applied in early stage and late stage cancer trials, enriching for patients potentially most likely to respond to therapy, accelerating time to trial readout, and identifying early relapsers.
Topics will include:
Angel Augusto Rodriguez, MD is a board certified medical oncologist who specializes in breast medical oncology and conducted clinical research with circulating tumor DNA. Before joining Natera, Dr. Rodriguez practiced at Austin Cancer Centers and Houston Methodist Cancer Center where he was Director of the Clinical Trials Office and the Triple Negative Breast Cancer Clinic. While at Houston Methodist he was principal investigator of clinical trials and conducted clinical research with circulating tumor DNA.
Reny Aniline, B.S, MBA is a Senior Director of BD in the oncology biopharma partnering group at Natera. He has more than 15 years of NGS and molecular diagnostics experience serving academic, clinical and biopharma clients.
Arsalan Arif is a news media entrepreneur who set out in 2015 to build his vision of an independent biotech news company at Endpoints News.